According to a new report, published by KBV research, The Global Infectious Respiratory Disease Diagnostics Market size is expected to reach $37.2 billion by 2028, rising at a market growth of -5.2% CAGR during the forecast period.
The Consumables market is leading the Global Infectious Respiratory Disease Diagnostics Market by Product Type in 2021; thereby, achieving a market value of $23.6 billion by 2028. This is due to the rising testing volumes, it is predicted that the segment will continue to dominate during the projection period. Reagents and reagent kits used for in vitro diagnostic testing for respiratory illnesses are part of the consumable category.
The RSV (Respiratory Syncytial Virus) market is exhibiting a CAGR of 18.2% during (2022 - 2028). Lung and respiratory tract infections are brought on by the respiratory syncytial virus (RSV). By the time they turn two, the majority of kids have the virus since it is so widespread. Adults can also contract the respiratory syncytial (sin-SISH-ul) virus. Due to this the cases of RSV is rising across the globe. Thus, the market for infectious respiratory disease diagnostics would grow in this segment.
The Saliva market acquired maximum revenue share in Global Infectious Respiratory Disease Diagnostics Market by Sample Type in 2021; thereby, achieving a market value of $12.4 billion by 2028. This rise is the result of both the pressing need for non-invasive tests and the growing use of samples in testing. The sensitivity and specificity of the saliva sample test were determined to be approximately 84.2% and 98.9%, respectively. As a result, industry participants began creating and marketing tests based on saliva rather than swabs.
The Immunoassay market is estimated to witness a CAGR of -4.1% during (2022 - 2028). In immunoassays, a bioanalytical technique, the response between an antigen (analyte) and an antibody determines how much of the analyte is quantified. This is due to factors including technological advances and the launch of cutting-edge technologies, the immunoassays segment is anticipated to grow at the quickest rate during the forecast period.
The Diagnostic Laboratories market is generating high revenue in the Global Infectious Respiratory Disease Diagnostics Market by End-use in 2021; thereby, achieving a market value of $17.2 billion by 2028. To tackle the COVID-19 disease's increased incidence, laboratories are also collaborating on strategic projects with a range of organizations to offer COVID-19 testing. To provide its real-time qPCR products as well as other laboratories. All these factors would contribute to market growth in this segment.
The Asia Pacific market dominated the Global Infectious Respiratory Disease Diagnostics Market by Region in 2021; thereby, achieving a market value of $13.0 billion by 2028. The Europe market is anticipated to grow at a CAGR of -5.6% during (2022 - 2028). Additionally, The North America market would witness a CAGR of -5.8% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/infectious-respiratory-disease-diagnostics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Becton, Dickinson and Company, Siemens Healthineers AG (Siemens AG), Thermo Fisher Scientific, Inc., Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Qiagen N.V., Bio-Rad Laboratories, Inc., Danaher Corporation, Quidel Corporation
By Product Type
By Application
By Sample Type
By Technology
By End Use
By Geography
Companies Profiled
Unique Offerings 
